The founder and CEO Vu Truing, Ph.D, recently had the honor of ringing the opening bell at the Nasdaq. Watch all the excitement here.
Aridis is developing new drug treatments for antibiotic-resistant infections.
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. They recently strengthened their IP with the issuance of additional broad patent coverage for two of its product candidate mAbs, AR-201and AR-401.
Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. They have a proven track record of innovation and successful drug development stewardship of therapeutic candidates from early discovery to commercial implementation.
Their current suite of anti-infective monoclonal antibodies is highly differentiated from conventional antibiotics, effective against all antibiotic resistant strains which the mAbs are directed against, and offers opportunities to profoundly impact current approaches to infection control.
We are proud that they call the BioCube San Jose, their home.
“The new patents granted speak to the novelty of our science --ensuring a strong intellectual property position around our various mAbs.Collectively, Aridis has worldwide exclusive rights to more than 110 issued patents and patents pending.